What is William Blair’s Forecast for AUTL FY2024 Earnings?

Autolus Therapeutics plc (NASDAQ:AUTL) – Investment analysts at William Blair lowered their FY2024 earnings per share estimates for shares of Autolus Therapeutics in a research report issued to clients and investors on Tuesday, November 12th. William Blair analyst M. Phipps now expects that the company will post earnings of ($1.09) per share for the year, down from their prior forecast of ($0.92). The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.84) per share. William Blair also issued estimates for Autolus Therapeutics’ Q4 2024 earnings at ($0.33) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.76) EPS and FY2027 earnings at ($0.53) EPS.

Separately, Needham & Company LLC restated a “buy” rating and issued a $9.00 target price on shares of Autolus Therapeutics in a report on Monday.

Autolus Therapeutics Stock Down 8.5 %

Shares of NASDAQ:AUTL opened at $3.01 on Friday. The firm has a 50 day simple moving average of $3.92 and a 200 day simple moving average of $3.99. Autolus Therapeutics has a 52 week low of $2.98 and a 52 week high of $7.45. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.55 and a current ratio of 18.55. The company has a market cap of $800.94 million, a PE ratio of -2.49 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same quarter in the prior year, the firm earned ($0.26) EPS.

Hedge Funds Weigh In On Autolus Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of AUTL. Renaissance Technologies LLC lifted its holdings in shares of Autolus Therapeutics by 253.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,145,056 shares of the company’s stock valued at $3,985,000 after buying an additional 821,156 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Autolus Therapeutics by 82.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock valued at $35,020,000 after acquiring an additional 2,487,778 shares during the last quarter. Millennium Management LLC grew its position in Autolus Therapeutics by 113.7% in the second quarter. Millennium Management LLC now owns 813,031 shares of the company’s stock worth $2,829,000 after acquiring an additional 432,503 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of Autolus Therapeutics by 2,603.8% during the 1st quarter. BNP Paribas Financial Markets now owns 115,399 shares of the company’s stock worth $736,000 after purchasing an additional 111,131 shares during the last quarter. Finally, Affinity Asset Advisors LLC raised its holdings in shares of Autolus Therapeutics by 27.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock valued at $14,964,000 after purchasing an additional 925,000 shares in the last quarter. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.